Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine

Abstract

We tested mood states in patients with systemic lupus erythematosus (SLE) treated with the prolactin-lowering drug, bromocriptine. Bromocriptine was given to seven patients in an open-label study to test its effects on active SLE. Two independent measures of SLE activity, the SLE Activity Measure (SLAM) and the SLE Disease Activity Index (SLEDAI), were scored and the Symptom Questionnaire (SQ) mood survey was administered at entry and at 6 monthly follow-up visits. The SLAM and SLEDAI scores improved significantly during treatment. Two of the four mood scales in the SQ (Anxiety Scale and Anger – Hostility Scale) showed significant improvement compared to the entry value at least once during treatment. Significant improvement was also observed in the Total Distress Score, which is the sum of the four scales and is a more sensitive measure of distress than the score of an individual scale. Depression, anxiety, somatic complaints, and total distress correlated positively with SLAM and/or SLEDAI scores. The Anxiety Scale and the Total Distress Score improved with treatment and did correlate positively with SLE activity. In contrast, the Anger – Hostility Scale improved with treatment but did not correlate with SLE activity.

Keywords

bromocriptine prolactin mood lupus autoimmunity therapy

Get full access to this article

View all access options for this article.

References

Tan EM , Cohen Al , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

McMurray R , Keisler D , Kanuckel K et al. Prolactin influences autoimmune disease activity in the female B/W mouse . J Immunol 1991; 147: 3780–3787 .

Jara LJ , Gomez-Sanchez C , Silveria LH et al. Hyperprolactinemia in systemic lupus erythematosus; association with disease . Am J Med Sci 1992; 303: 222–226 .

Jara-Quezada L , Graef A , Lavalle C . Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus . J Rheumatol 1991; 18: 349–353 .

Lavalle C , Loyo E , Panaigua R et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus . J Rheumatol 1987; 14: 268–272 .

McMurray RW , Allen SH , Braun AL et al. Longstanding hyperprolactinemia associated with systemic lupus erythematosus: possible hormonal stimulation of an autoimmune disease . J Rheumatol 1994; 21: 843–850 .

McMurray RW , Weidensaul D , Allen SH , Walker SE . Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus . J Rheumatol 1995; 22: 2084–2091 .

Kozora E , Thompson LL , West ST , Kotzin BL . Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease . Arthritis Rheum 1996; 39: 2035–2045 .

Kellner R . A symptom questionnaire . J Clin Psych 1987; 48: 268–274 .

10.

Kellner R. Manual of the Symptom Questionnaire. Available from the author. Department of Psychiatry, School of Medicine, 2400 Tucker NE, Albuquerque, NM 87131, USA, 1987.

11.

Fava GA , Fava M , Kellner R et al. Depression, hostility and anxiety in hyperprolactinemic amenorrhea . Psychother Psychosom 1981; 36: 122–128 .

12.

Kellner R , Buckman MT , Fava GA , Pathak D . Hyperprolactinemia, distress, and hostility . Am J Psychiatry 1984; 141: 759–763 .

13.

Buckman MT , Kellner R . Reduction of distress in hyperprolactinemia with bromocriptine . Am J Psychiatry 1985; 142: 242–244 .

14.

Liang MH , Socher SA , Larson MG et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum 1989; 32: 1107–1118 .

15.

Bombardier C , Gladman DD , Urowitz MB et al. Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients . Arthritis Rheum 1992; 35: 630–640 .

16.

Kellner R . The symptom-rating test. In: Sartorius N , Ban TA (eds). Assessment of Depression. Berlin: Springer-Verlag , 1986, pp 213–220.

17.

Feinglass EJ , Arnett FC , Dorsch CA et al. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease . Medicine 1976; 55: 323–339 .

18.

West SG , Emlen W , Wener MH , Kotzin BL . Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests . Am J Med 1995; 99: 153–163 .

19.

Shapiro HS . Psychopathology in the patient with lupus. In: Wallace DJ , Hahn BH (eds). Dubois' Lupus Erythematosus, 5th edn. Williams & Wilkins: Baltimore , 1997, pp 755–782.

20.

Carbotte RM , Denburg SD , Denburg JA . Prevalence of cognitive impairment in systemic lupus erythematosus . J Nerv Mental Dis 1986; 174: 357–364 .

21.

Hanly JG , Liang MH . Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues . Ann NY Acad Sci 1997; 823: 60–68 .

22.

Mitchell WD , Thompson TL . Psychiatric distress in systemic lupus erythematosus outpatients . Psychosomatics 1990; 31: 293–300 .

23.

Hanly JG , Sherwood G , Eastwood B . Clinical course of cognitive dysfunction in systemic lupus erythematosus . J Rheumatol 1994; 21: 1825–1831 .

24.

Hall RCW , Stickney SK , Gardner ER . Psychiatric symptoms in patients with systemic lupus erythematosus . Psychosomatics 1981; 22: 15–24 .

25.

Kremer JM , Rynes RI , Bartholomew LE et al. Non-organic nonpsychotic psychopathology (NONPP) in patients with systemic lupus erythematosus . Semin Arthritis Rheum 1981; 11: 182–189 .

26.

Kellner R , Sheffield BF . The relief of distress following attendance at a clinic . Br J Psychiat 1971; 118: 195–198 .

27.

Colonna L , Petit M , Lepine JP . Bromocriptine in affective disorders. A pilot study . J Affect Disord 1979; 1: 173–177 .

28.

Bouras N , Bridges PK . Bromocriptine in depression . Cur Med Res Opin 1982; 8: 150–153 .

29.

Inoue T , Tsuchiya K , Miura J et al. Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression . Biol Psychiatry 1996; 40: 151–153 .

30.

Waehrens J , Gerlach J . Bromocriptine and imipramine in endogenous depression. A double blind controlled trial in out-patients . J Affect Disord 1981; 3: 193–202 .